Compare AN & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AN | SYRE |
|---|---|---|
| Founded | 1991 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.3B |
| IPO Year | 1995 | 2015 |
| Metric | AN | SYRE |
|---|---|---|
| Price | $184.23 | $73.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $244.33 | $85.08 |
| AVG Volume (30 Days) | 352.7K | ★ 941.4K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.71 | N/A |
| EPS | ★ 5.85 | N/A |
| Revenue | ★ $27,631,400,000.00 | N/A |
| Revenue This Year | $4.32 | N/A |
| Revenue Next Year | $2.89 | N/A |
| P/E Ratio | $31.38 | ★ N/A |
| Revenue Growth | ★ 3.24 | N/A |
| 52 Week Low | $176.62 | $13.93 |
| 52 Week High | $228.92 | $78.80 |
| Indicator | AN | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 39.55 | 56.62 |
| Support Level | N/A | $67.18 |
| Resistance Level | $214.85 | $76.16 |
| Average True Range (ATR) | 6.12 | 4.18 |
| MACD | -2.24 | -1.19 |
| Stochastic Oscillator | 29.71 | 57.96 |
AutoNation is the second-largest automotive dealer in the United States, with 2025 revenue of $27.6 billion and over 240 dealerships, plus 52 collision centers. The firm also has 26 AutoNation USA used-vehicle stores, a captive lender, four auction sites, and three parts distributors across 20 states primarily in Sunbelt metropolitan areas. New-vehicle sales account for nearly half of revenue; the company also sells used vehicles, parts, and repair services as well as auto financing. The company (formerly Republic Industries) divested its waste management unit (Republic Services) in 1999 and its car rental businesses (ANC Rental) in 2000. Wayne Huizenga founded the company in the 1990s to bring the rollup acquisition strategy to auto retailing, which has proved to be a smart move.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.